Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 2/20 | 0.57 |
| ▸ | NPC1 | O15118 | 7/20 | 0.54 |
| ▸ | RAB9A | P51151 | 7/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.54 |
| ▸ | TP53 | P04637 | 3/20 | 0.54 |
| ▸ | HTT | P42858 | 2/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | PAX8 | Q06710 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.49 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.49 |
| ▸ | RELA | Q04206 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | GRM5 | P41594 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9402370 | 0.85 | NCF1 (0.53) | NCF1NPC1RAB9AKDM4ESMN1; SMN2 | |
| SCHEMBL10458402 | 0.83 | NCF1 (0.71) | NCF1NPC1RAB9AKDM4ESMN1; SMN2 | |
| SCHEMBL30760998 | 0.83 | NCF1 (0.71) | NCF1NPC1RAB9AKDM4ESMN1; SMN2 | |
| SCHEMBL1702119 | 0.83 | NPC1 (0.59) | NCF1NPC1RAB9AKDM4ESMN1; SMN2 | |
| SCHEMBL2844247 | 0.83 | NPC1 (0.59) | NCF1NPC1RAB9AKDM4ESMN1; SMN2 | |
| SCHEMBL1703116 | 0.77 | PDGFRB (0.65) | NPC1RAB9AKDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL1702696 | 0.76 | NCF1 (0.51) | NCF1NPC1RAB9AKDM4ESMN1; SMN2 | |
| SCHEMBL17995328 | 0.76 | NPC1 (0.52) | NCF1NPC1RAB9AKDM4ESMN1; SMN2 | |
| SCHEMBL22134928 | 0.76 | NPC1 (0.49) | NCF1NPC1RAB9AKDM4ESMN1; SMN2 | |
| SCHEMBL396525 | 0.76 | NCF1 (0.61) | NCF1NPC1RAB9AKDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 122 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2440546-B1 | COMPOUNDS USEFUL FOR TREATING PREMATURE AGING AND IN PARTICULAR PROGERIA | ABIVAX (FR) | 2022-12-28 | — | — | EP | claimed |
| US-11014918-B2 | Compounds and pharmaceutical compositions containing at least one of the compounds | ABIVAX (FR) | 2021-05-25 | — | — | US | claimed |
| US-20200172525-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING AT LEAST ONE OF THE COMPOUNDS | ABIVAX (FR) | 2020-06-04 | — | — | US | claimed |
| US-20180339981-A1 | COMPOUNDS FOR PREVENTING, INHIBITING, OR TREATING CANCER, AIDS AND/OR PREMATURE AGING | ABIVAX (FR) | 2018-11-29 | — | — | US | claimed |
| US-9827237-B2 | Compounds useful for treating diseases caused by retroviruses | ABIVAX (FR) | 2017-11-28 | — | — | US | claimed |
| US-20160151348-A1 | COMPOUNDS USEFUL FOR TREATING DISEASES CAUSED BY RETROVIRUSES | ABIVAX (FR) | 2016-06-02 | — | — | US | claimed |
| EP-3016656-A1 | BICYCLIC COMPOUNDS USEFUL FOR TREATING DISEASES CAUSED BY RETROVIRUSES | ABIVAX (FR) | 2016-05-11 | — | — | EP | claimed |
| US-9108919-B2 | Compounds useful for treating cancer | ABIVAX (FR) | 2015-08-18 | — | — | US | claimed |
| WO-2015001518-A1 | BICYCLIC COMPOUNDS USEFUL FOR TREATING DISEASES CAUSED BY RETROVIRUSES | SPLICOS (FR) | 2015-01-08 | — | — | WO | claimed |
| US-20140080831-A1 | COMPOUNDS USEFUL FOR TREATING CANCER | CENTRE NATIONALE DE RECHERCHE SCIENTIFIQUE (FR) | 2014-03-20 | — | — | US | claimed |
| US-20120329796-A1 | COMPOUNDS USEFUL FOR TREATING PREMATURE AGING AND IN PARTICULAR PROGERIA | SOCIETE SPLICOS (FR) | 2012-12-27 | — | — | US | claimed |
| US-20120283265-A1 | COMPOUNDS USEFUL FOR TREATING AIDS | SOCIETE SPLICOS (FR) | 2012-11-08 | — | — | US | claimed |
| US-20120277230-A1 | COMPOUNDS USEFUL FOR TREATING CANCER | SOCIETE SPLICOS (FR) | 2012-11-01 | — | — | US | claimed |
| EP-2440546-A2 | COMPOUNDS USEFUL FOR TREATING PREMATURE AGING AND IN PARTICULAR PROGERIA | Société Splicos (FR) | 2012-04-18 | — | — | EP | claimed |
| WO-2010143170-A2 | COMPOUNDS USEFUL FOR TREATING PREMATURE AGING AND IN PARTICULAR PROGERIA | SOCIÉTÉ SPLICOS (FR) | 2010-12-16 | — | — | WO | claimed |
| US-20240343716-A1 | COMPOUNDS FOR PREVENTING, INHIBITING, OR TREATING CANCER, AIDS AND/OR PREMATURE AGING | ABIVAX (FR) | 2024-10-17 | — | — | US | disclosed |
| EP-3521283-B1 | COMPOUNDS USEFUL FOR TREATING CANCER | ABIVAX (FR) | 2024-02-28 | — | — | EP | disclosed |
| EP-1828142-A1 | METHOD FOR PRODUCING ONIUM ALKYL SULFATES WITH A LOW HALOGENIDE CONTENT | Merck Patent GmbH (DE) | 2007-09-05 | — | — | EP | disclosed |
| WO-2006123165-A2 | PYRIMIDINE DERIVATIVES AS HSP90 INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2006-11-23 | — | — | WO | disclosed |
| WO-2006063654-A1 | METHOD FOR PRODUCING ONIUM ALKYL SULFATES WITH A LOW HALOGENIDE CONTENT | MERCK PATENT GMBH (DE) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283265-A1 | COMPOUNDS USEFUL FOR TREATING AIDS | CBR1, CNR1, CBR3 | NCF1 632/4885NPC1 45/4885RAB9A 4149/4885 |
| US-20120277230-A1 | COMPOUNDS USEFUL FOR TREATING CANCER | CBR1, CBR3, NCOR1 | NCF1 717/4885NPC1 129/4885RAB9A 4050/4885 |
| US-11014918-B2 | Compounds and pharmaceutical compositions containing at least one of the compounds | TP53, BRCA1, LIMS1 | NCF1 2955/4885NPC1 19/4885RAB9A 351/4885 |
| US-20240343716-A1 | COMPOUNDS FOR PREVENTING, INHIBITING, OR TREATING CANCER, AIDS AND/OR PREMATURE AGING | RCOR1, NR3C1, NR5A1 | NCF1 1523/4885NPC1 80/4885RAB9A 2148/4885 |
| US-20120329796-A1 | COMPOUNDS USEFUL FOR TREATING PREMATURE AGING AND IN PARTICULAR PROGERIA | NR2C2, NCOR2, NR4A2 | NCF1 834/4885NPC1 144/4885RAB9A 4270/4885 |
| US-20180339981-A1 | COMPOUNDS FOR PREVENTING, INHIBITING, OR TREATING CANCER, AIDS AND/OR PREMATURE AGING | RCOR1, NR3C1, NR5A1 | NCF1 1523/4885NPC1 80/4885RAB9A 2148/4885 |
| US-20160151348-A1 | COMPOUNDS USEFUL FOR TREATING DISEASES CAUSED BY RETROVIRUSES | RCOR1, CBR1, RCOR3 | NCF1 731/4885NPC1 126/4885RAB9A 3396/4885 |
| US-20200172525-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING AT LEAST ONE OF THE COMPOUNDS | TP53, BRCA1, LIMS1 | NCF1 2955/4885NPC1 19/4885RAB9A 351/4885 |
| US-20140080831-A1 | COMPOUNDS USEFUL FOR TREATING CANCER | NR1H4, NR1H3, NCOR1 | NCF1 810/4885NPC1 60/4885RAB9A 1904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.